Moderna’s sign is seen outside of their headquarters in Cambridge, MA on March 11, 2021.
Boston Globe | Getty Images
Moderna shares fell by more than 11% on Thursday after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.
The company said some doses for delivery this year have been shifted to early 2022 amid production issues and as it prioritizes deliveries to low-income countries through COVAX, the U.N.-backed effort to share coronavirus vaccines. It now expects Covid vaccine sales of between $15 billion and $18 billion from $20 billion this year.
In releasing its third-quarter earnings, Moderna said it is now expecting to deliver between 700 million and 800 million doses this year, down from its previous expectations of between 800 million and 1 billion doses. The company also said it expects sales of $17 billion to $22 billion in 2022.
By comparison, Pfizer has said it expects Covid vaccine sales of $36 billion this year and $29 billion in 2022.
Here’s how Moderna did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:
- EPS: $7.70 per share versus $9.05 per share expected
- Revenue: $4.97 billion versus $6.21 billion expected
“We are humbled to have helped hundreds of millions of people around the world with our COVID-19 vaccine and yet we know our work is not done,” Moderna CEO Stephane Bancel said in a statement.
He said the company is working to ensure the vaccine is available in low-income countries with approximately 10% of its 2021 volume, and “significantly more” volume next year.
Moderna’s Covid vaccine is its only commercialized product. The earnings report comes two weeks after the Food and Drug Administration authorized booster shots of Moderna’s vaccine to tens of millions of Americans.
The company said Thursday it anticipates commercial booster market sales could be up to $2 billion in 2022.